Pfizer, Ionis will feel the blow of COVID-19 on the fast-growing ATTR market: report
SVBLeerink analysts had expected sales of Pfizer's hot new drug Vyndaqel to treat ATTR cardiomyopathy to come in at $2.34 billion this year. Then COVID-19 struck, delaying diagnoses and dampening expectations—not just for Vyndaqel, but for Ionis' rival drug Tegsedi. Can they catch up after the pandemic ends?
COVID-19 lockdown in India hub leaves pharmas scrambling to keep up supply
With a major Indian production hub now locked down in a COVID-19 containment zone, the spotlight on pharma's emerging markets suppliers will likely shine even hotter.
J&J, AbbVie's Imbruvica pads CLL lead with FDA green light in younger patients
Many chronic lymphocytic leukemia patients start on Johnson & Johnson and AbbVie’s Imbruvica, a blockbuster that until recently had five different approvals in the disease. Thanks to a sixth granted by the FDA Tuesday, younger, fitter patients can now start on it, too.
Coronavirus tracker: Gilead hoping to read out new remdesivir data early
After taking its lumps in an inconclusive Chinese study in severe COVID-19 patients, Gilead Sciences is reportedly ready to read out results from a major study of investigational candidate remdesivir as soon as May.
Pfizer promotes prescription drug help and the power of science in new TV ads aimed at COVID-19 concerns
In new TV ads, Pfizer is tackling two key concerns brought on by the COVID-19 pandemic. The first commercial addresses how people struggling with unemployment or insurance loss can get help paying for prescription medicines, while the second tackles the uncertainty and anxiety many people feel right now, assuring viewers that “science will win.”
Early treatment with Novartis' Mayzent stalls secondary progressive MS: study
Novartis is looking to grow its new multiple sclerosis drug Mayzent in a crowded field, and, with Gilenya generics threatening, the newer MS medicine may need to carry even more weight. Tuesday, it racked up some new data that could help.
Bristol Myers, Exelixis scored a kidney cancer combo win. But is there room for their duo on the market?
Bristol Myers Squibb and Exelixis have a potential kidney cancer contender on their hands with their Opdivo-Cabometyx combo. But the duo will have to meet a “high bar” to gain traction in the crowded field, one analyst says.
Immunomedics finally wins its blockbuster FDA nod for Trodelvy in triple-negative breast cancer
Immunomedics has weathered two FDA snubs to win a blockbuster approval for its antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer. And the company plans to launch right away despite the COVID-19 pandemic.
A bull's-eye from 24 feet? COVID-19 vaccine timelines are overly hopeful, analyst says
Americans have been told daily—by politicians, by experts, by the media—that researchers are urgently working on COVID-19 vaccines, and that one might be available in 12 to 18 months. But one analyst says he doesn't see it happening. Here's why.
Merck KGaA amps up in gene therapy with $110M viral vector manufacturing boost
Merck KGaA and subsidiary MilliporeSigma made a big bet on gene therapy by expanding their viral vector manufacturing facility in California in 2016. Now, the German drugmaker is doubling down on that bet and investing a hefty nine figures into expanding the facility even further.